- ►annals.org [PDF] G Merli, TE Spiro, CG Olsson, U Abildgaard, … - Annals of internal medicine, 2001 - Am Coll Physicians Background: Low-molecular-weight heparins administered sub- cutaneously once or
twice daily have been reported to be as safe and efficacious as intravenous
unfractionated heparin in the treat- ment of acute venous thromboembolic ... Cited by 221 - Related articles - BL Direct - All 11 versions
HK Breddin, V Hach-Wunderle, R Nakov, VV … - New England Journal of Medicine, 2001 - content.nejm.org Methods In this multicenter, open-label study with blinded adjudication of end
points, we randomly assigned patients with acute deep-vein thrombosis to one of
three treatment regimens: intravenous administration of unfractionated ... Cited by 129 - Related articles - BL Direct - All 5 versions
LR Dolovich, JS Ginsberg, JD Douketis, AM … - Archives of Internal Medicine, 2000 - Am Med Assoc Results Thirteen studies were included. There was no statistically significant
difference in risk between UFH and LMWHs for recurrent VTE (RR, 0.85 [95% CI,
0.65-1.12]), pulmonary embolism (RR, 1.02 [95% CI, 0.64-1.62]), major ... Cited by 393 - Related articles - BL Direct - All 5 versions
RD Hull, GE Raskob, RF Brant, GF Pineo, G … - Archives of Internal Medicine, 2000 - archinte.highwire.org Background Pulmonary embolism (PE) occurs in 50% or more of patients with
proximal deep-vein thrombosis. Low-molecular-weight heparin treatment is
effective and safe in patients with deep vein thrombosis and may also be so ... Cited by 145 - Related articles - BL Direct - All 6 versions
G Simonneau, H Sors, B Charbonnier, Y Page, … - The New England journal of medicine, 1997 - nejm.highwire.org Results In the first eight days of treatment, 9 of 308 patients assigned to
receive unfractionated heparin (2.9 percent) reached at least one of the end
points, as compared with 9 of 304 patients assigned to low-molecular-weight ... Cited by 634 - Related articles - BL Direct - All 11 versions
MJ Kovacs, D Anderson, B Morrow, L Gray, D … - Thrombosis and haemostasis, 2000 - ncbi.nlm.nih.gov BACKGROUND: Pulmonary embolism is a common complication of deep vein thrombosis.
It has been established that low molecular weight heparin may be used to treat
deep vein thrombosis or pulmonary embolism and randomized studies have ... Cited by 145 - Related articles - BL Direct - All 4 versions
G Simonneau, B Charbonnier, H Decousus, B … - Archives of internal medicine, 1993 - ncbi.nlm.nih.gov BACKGROUND: A low-molecular-weight heparin, enoxaparin sodium, has been shown to
be effective and safe in preventing deep vein thrombosis both in general surgery
and in high-risk orthopedic surgery. We conducted a controlled, randomized ... Cited by 177 - Related articles - All 2 versions
- ►annals.org [PDF] MK Gould, AD Dembitzer, RL Doyle, TJ … - Annals of internal medicine, 1999 - Am Coll Physicians Michael K. Gould, MD, MSc; Anne D. Dembitzer, MD; Ramona L. Doyle, MD; Trevor J.
Hastie, PhD; and Alan M. Garber, MD, PhD ... Background: Low-molecular-weight
heparins may sim- plify the management of deep venous thrombosis. A criti- ... Cited by 441 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] HR Buller, BL Davidson, H Decousus, A … - Annals of internal medicine, 2004 - Am Coll Physicians Background: The current standard initial therapies for deep venous thrombosis
are low-molecular-weight heparin and unfrac- tionated heparin. In a dose-ranging
study of patients with symp- tomatic deep venous thrombosis, fondaparinux ... Cited by 235 - Related articles - BL Direct - All 13 versions
